510 related articles for article (PubMed ID: 27129276)
1. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Bröer A; Rahimi F; Bröer S
J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
[TBL] [Abstract][Full Text] [Related]
2. Ablation of the
Bröer A; Gauthier-Coles G; Rahimi F; van Geldermalsen M; Dorsch D; Wegener A; Holst J; Bröer S
J Biol Chem; 2019 Mar; 294(11):4012-4026. PubMed ID: 30635397
[TBL] [Abstract][Full Text] [Related]
3. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
4. Disruption of Amino Acid Homeostasis by Novel ASCT2 Inhibitors Involves Multiple Targets.
Bröer A; Fairweather S; Bröer S
Front Pharmacol; 2018; 9():785. PubMed ID: 30072900
[TBL] [Abstract][Full Text] [Related]
5. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
6. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
7. TFEB controls retromer expression in response to nutrient availability.
Curnock R; Calcagni A; Ballabio A; Cullen PJ
J Cell Biol; 2019 Dec; 218(12):3954-3966. PubMed ID: 31694921
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.
Kandasamy P; Zlobec I; Nydegger DT; Pujol-Giménez J; Bhardwaj R; Shirasawa S; Tsunoda T; Hediger MA
Mol Oncol; 2021 Oct; 15(10):2782-2800. PubMed ID: 34003553
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2.
Okudaira H; Nakanishi T; Oka S; Kobayashi M; Tamagami H; Schuster DM; Goodman MM; Shirakami Y; Tamai I; Kawai K
Nucl Med Biol; 2013 Jul; 40(5):670-5. PubMed ID: 23647854
[TBL] [Abstract][Full Text] [Related]
10. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
11. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
12. Sorting nexin 27 (SNX27) regulates the trafficking and activity of the glutamine transporter ASCT2.
Yang Z; Follett J; Kerr MC; Clairfeuille T; Chandra M; Collins BM; Teasdale RD
J Biol Chem; 2018 May; 293(18):6802-6811. PubMed ID: 29563155
[TBL] [Abstract][Full Text] [Related]
13. SLC38A2 Overexpression Induces a Cancer-like Metabolic Profile and Cooperates with SLC1A5 in Pan-cancer Prognosis.
Huang MS; Chang JH; Lin WC; Cheng YH; Li FA; Suen CS; Hwang MJ; Chang CK; Mou KY
Chem Asian J; 2020 Nov; 15(22):3861-3872. PubMed ID: 32996252
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.
Polet F; Martherus R; Corbet C; Pinto A; Feron O
Oncotarget; 2016 Jul; 7(29):46371-46383. PubMed ID: 27344174
[TBL] [Abstract][Full Text] [Related]
15. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
16. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
17. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
18. LncRNA
Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
[TBL] [Abstract][Full Text] [Related]
19. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
20. The role of the glutamine transporter ASCT2 in antineoplastic therapy.
Teixeira E; Silva C; Martel F
Cancer Chemother Pharmacol; 2021 Apr; 87(4):447-464. PubMed ID: 33464409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]